Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials.

Richard R. Furman,John C. Byrd,Roger G. Owen,Susan OBrien,Jennifer R. Brown,Peter Hillmen,Deborah M. Stephens,Priti Patel,Liat Schwartz-Sagi,Marshall Baek,Beth Christian,Martin J. S. Dyer,Matthew Streetly,Clare Sun,Simon Rule,Michael Wang,Paolo Ghia,Wojciech Jurczak,John M. Pagel,Jeff P. Sharman

Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials.

2020

8064Background: Acala is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved in the US for patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocyt...

Keywords:

Physical therapy
pooled analysis
Clinical trial
Internal medicine
Medicine
Acalabrutinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations